Entasis Therapeutics Holdings Inc. ETTX
2.19 0.00 (+0.00%)
At closeJul 8, 2022, 4:00 PM EDT
2.19 Day range 2.20
52-week range unavailable
Analyst view
Consensus: hold
Hold
Price target (mean) 2.00
Ratings (0m) 3 3 buy · 0 hold · 0 sell
- Strong buy1
- Buy2
- Hold0
- Sell0
- Strong sell0
Recommendation trend
- This month 3
- 1 month ago 4
- 2 months ago 4
Earnings and revenue estimates
Consensus for the coming quarters and fiscal years
| Period | EPS estimate | Low – high | Year ago | EPS growth | Revenue estimate | Revenue growth | Analysts |
|---|---|---|---|---|---|---|---|
| Current quarter | -0.29 | -0.32 – -0.28 | -0.29 | 0.0% | 0 | 0.0% | 3 |
| Next quarter | -0.30 | -0.38 – -0.24 | -0.26 | -15.4% | 0 | 0.0% | 3 |
| Current year | -1.20 | -1.31 – -1.08 | -1.09 | -10.1% | 0 | 0.0% | 3 |
| Next year | -1.15 | -1.24 – -1.06 | -1.20 | +4.2% | 10.67M | 0.0% | 2 |
Upgrades and downgrades
The latest rating changes
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| May 5, 2022 | Cantor Fitzgerald | Downgrade | Overweight | Neutral |
| Mar 15, 2022 | Alliance Global Partners | Downgrade | Buy | Neutral |
| Mar 7, 2022 | Wedbush | Downgrade | Outperform | Neutral |
| Mar 3, 2022 | HC Wainwright & Co. | Downgrade | Buy | Neutral |
| Oct 19, 2021 | BMO Capital | Maintained | — | Outperform |
| Oct 18, 2021 | HC Wainwright & Co. | Maintained | — | Buy |
| Sep 8, 2020 | Cantor Fitzgerald | Initiated | — | Overweight |
| Jul 12, 2020 | Roth Capital | Initiated | — | Buy |
| Apr 13, 2020 | H.C. Wainwright | Maintained | — | Buy |
| Mar 11, 2020 | Credit Suisse | Maintained | — | Outperform |
| Aug 18, 2019 | H.C. Wainwright | Initiated | — | Buy |
| Oct 23, 2018 | SunTrust Robinson Humphrey | Initiated | — | Buy |
| Oct 21, 2018 | Wedbush | Initiated | — | Outperform |
| Oct 21, 2018 | BMO Capital | Initiated | — | Outperform |